Coeptis Therapeutics Valuation
| COEP Stock | USD 10.45 0.65 5.86% |
At this time, the firm appears to be overvalued. Coeptis Therapeutics shows a prevailing Real Value of $5.71 per share. The current price of the firm is $10.45. Our model approximates the value of Coeptis Therapeutics from analyzing the firm fundamentals such as return on equity of -14.81, and Current Valuation of 36.62 M as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Coeptis Therapeutics' price fluctuation is dangerous at this time. Calculation of the real value of Coeptis Therapeutics is based on 3 months time horizon. Increasing Coeptis Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Coeptis Therapeutics' intrinsic value may or may not be the same as its current market price of 10.45, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 10.45 | Real 5.71 | Hype 10.65 |
The intrinsic value of Coeptis Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Coeptis Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Coeptis Therapeutics helps investors to forecast how Coeptis stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Coeptis Therapeutics more accurately as focusing exclusively on Coeptis Therapeutics' fundamentals will not take into account other important factors: Coeptis Therapeutics Total Value Analysis
Coeptis Therapeutics is currently forecasted to have valuation of 36.62 M with market capitalization of 8.06 M, debt of 1.22 M, and cash on hands of 2.38 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Coeptis Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
36.62 M | 8.06 M | 1.22 M | 2.38 M |
Coeptis Therapeutics Asset Utilization
One of the ways to look at asset utilization of Coeptis is to check how much profit was generated for every dollar of assets it reports. Coeptis Therapeutics shows a negative utilization of assets of -1.87 percent, losing $0.0187 for each dollar of assets held by the firm. Unsuccessful asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Coeptis Therapeutics shows how unproductive it operates for each dollar spent on its assets.Coeptis Therapeutics Ownership Allocation
Coeptis Therapeutics holds a total of 39.72 Million outstanding shares. Coeptis Therapeutics shows 18.53 percent of its outstanding shares held by insiders and 4.06 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Coeptis Therapeutics Profitability Analysis
Net Loss for the year was (21.27 M) with profit before overhead, payroll, taxes, and interest of 75 K.About Coeptis Therapeutics Valuation
The stock valuation mechanism determines Coeptis Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Coeptis Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Coeptis Therapeutics. We calculate exposure to Coeptis Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Coeptis Therapeutics's related companies.Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Coeptis Therapeutics Holdings, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania. Coeptis Therapeutics is traded on NASDAQ Exchange in the United States.
Coeptis Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Coeptis Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 25.7 M |
Additional Tools for Coeptis Stock Analysis
When running Coeptis Therapeutics' price analysis, check to measure Coeptis Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coeptis Therapeutics is operating at the current time. Most of Coeptis Therapeutics' value examination focuses on studying past and present price action to predict the probability of Coeptis Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coeptis Therapeutics' price. Additionally, you may evaluate how the addition of Coeptis Therapeutics to your portfolios can decrease your overall portfolio volatility.